ProCE Banner Activity

PARP Inhibitor Combinations in Prostate Cancer: Current Clinical Evidence and Key Ongoing Trials

Slideset Download
Download these slides from a live Webinar to review the most recent clinical data on PARP inhibitors in combination with other agents in metastatic castration-resistant prostate cancer.

Released: June 14, 2021

Expiration: June 13, 2022

No longer available for credit.

Share

Faculty

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Program Director Disclosure

Program Director

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California